Brijnath Bianca, Xia Ting, Turner Lyle, Mazza Danielle
School of Occupational Therapy and Social Work, Faculty of Health Sciences, Curtin University, Building 401, Bentley Campus, Perth, 6152, Australia.
Department of General Practice, School of Primary Care, Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne, Australia.
BMC Psychiatry. 2017 Jun 6;17(1):214. doi: 10.1186/s12888-017-1375-2.
Current clinical guidelines recommend non-pharmacological interventions as first-line treatments for young patients aged 16-24 years with a mental health condition (MHC). However, several studies have noted increasing trends in psychotropic prescribing for this age group, especially in antidepressant prescribing. In Australia, the vast majority of psychotropic medications prescribed to young people come from the general practice setting. To assess whether Australian General Practitioners (GPs) are prescribing in accordance with clinical guideline recommendations, this study examined trends in GP prescribing of psychotropic medications to young patients aged 16-24 years.
We performed a retrospective analysis of routine general practice data from 9112 patients aged 16-24 years with a MHC. Data were extracted from the Melbourne East Monash General Practice Database from 1/01/2009 to 31/12/2014. The main outcome measures included the number of consultations for patients with MHCs, psychotropic prescribing by GPs, and patient characteristics associated with the likelihood of being prescribed a psychotropic.
In total, 9112 out of a total of 77,466 young patients were identified as having a MHC in this study, and 11,934 psychotropic prescriptions were provided to 3967 (43.5%) of them over the study period. Antidepressants accounted for 81.4% of total psychotropic prescriptions, followed by anxiolytics (9.6%) and antipsychotics (9.0%). The number of prescriptions issued to individuals with MHCs increased over time. Women and patients aged 21-24 years had higher incidence rates for prescription than men and those aged 16-17 (IRR: 1.15, 95% CI 1.08-1.22, IRR: 1.93, 95% CI 1.750-2.11).
Our findings demonstrate an increasing trend in GP prescribing of psychotropics to young people over the study period with higher levels of prescribing to women and those 21-24 years of age. Although GP prescribing corresponded with guideline recommendations on the whole, there were discrepancies between GP's antidepressant prescribing and guideline recommendations, reasons for which were unclear. Research is needed to investigate GPs decision-making processes underlying their prescribing, to target interventions to improve existing data in GP records to improve management, and to identify areas of further training if needed to facilitate greater concordance between clinical practice and guideline recommendations.
当前临床指南推荐将非药物干预作为16 - 24岁患有精神健康疾病(MHC)的年轻患者的一线治疗方法。然而,多项研究指出该年龄组精神药物处方呈上升趋势,尤其是抗抑郁药处方。在澳大利亚,开给年轻人的绝大多数精神药物来自全科医疗环境。为评估澳大利亚全科医生(GP)的处方是否符合临床指南建议,本研究调查了GP给16 - 24岁年轻患者开具精神药物的趋势。
我们对9112名16 - 24岁患有MHC的患者的常规全科医疗数据进行了回顾性分析。数据从墨尔本东部莫纳什全科医疗数据库中提取,时间跨度为2009年1月1日至2014年12月31日。主要结局指标包括患有MHC的患者的会诊次数、GP开具的精神药物处方以及与开具精神药物可能性相关的患者特征。
在本研究中,总共77466名年轻患者中有9112名被确定患有MHC,在研究期间,共向其中3967名(43.5%)患者开具了11934张精神药物处方。抗抑郁药占精神药物处方总数的81.4%,其次是抗焦虑药(9.6%)和抗精神病药(9.0%)。发给患有MHC的个体的处方数量随时间增加。女性和21 - 24岁的患者的处方发生率高于男性和16 - 17岁的患者(发病率比值比:1.15,95%置信区间1.08 - 1.22;发病率比值比:1.93,95%置信区间1.750 - 2.11)。
我们的研究结果表明,在研究期间,GP给年轻人开具精神药物的趋势呈上升,女性和21 - 24岁人群的处方量更高。虽然GP的处方总体上符合指南建议,但GP的抗抑郁药处方与指南建议之间存在差异,原因尚不清楚。需要开展研究以调查GP处方背后的决策过程,针对干预措施以改善GP记录中的现有数据以改进管理,并确定是否需要进一步培训的领域以促进临床实践与指南建议之间更大程度的一致性。